ELLENCE Drug Patent Profile
Which patents cover Ellence, and when can generic versions of Ellence launch?
Ellence is a drug marketed by Pfizer Inc and is included in one NDA.
The generic ingredient in ELLENCE is epirubicin hydrochloride. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the epirubicin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ellence
A generic version of ELLENCE was approved as epirubicin hydrochloride by HIKMA on June 27th, 2007.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ELLENCE?
- What are the global sales for ELLENCE?
- What is Average Wholesale Price for ELLENCE?
Summary for ELLENCE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 67 |
| Clinical Trials: | 21 |
| Patent Applications: | 6,461 |
| Drug Prices: | Drug price information for ELLENCE |
| What excipients (inactive ingredients) are in ELLENCE? | ELLENCE excipients list |
| DailyMed Link: | ELLENCE at DailyMed |
Recent Clinical Trials for ELLENCE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Cancer Institute (NCI) | Phase 2 |
| OHSU Knight Cancer Institute | Phase 2 |
| Bayer | Phase 2 |
Pharmacology for ELLENCE
| Drug Class | Anthracycline Topoisomerase Inhibitor |
| Mechanism of Action | Topoisomerase Inhibitors |
US Patents and Regulatory Information for ELLENCE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer Inc | ELLENCE | epirubicin hydrochloride | INJECTABLE;INJECTION | 050778-001 | Sep 15, 1999 | AP | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Pfizer Inc | ELLENCE | epirubicin hydrochloride | INJECTABLE;INJECTION | 050778-002 | Sep 15, 1999 | AP | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
